Impurity quantification is essential for understanding product quality, process consistency, and material stability during drug development. Pharmaceutical teams often need more than a simple impurity percentage—they need reliable analytical data that shows which impurities are present, how much is actually there, how impurity levels change across batches or stress conditions, and whether existing methods can truly separate and quantify those components with confidence. BOC Sciences provides impurity quantification services built around these practical development needs, including quantitative method development, related substance analysis, degradation product monitoring, trace impurity measurement, orthogonal confirmation, and impurity trend evaluation. Our team helps clients turn complex chromatographic and spectrometric data into clear, decision-ready results that support process optimization, analytical troubleshooting, formulation assessment, and overall impurity control strategy.
We design quantitative workflows for known and unknown related substances using orthogonal separation strategies and robust data review, often integrating our broader analytical platform for complex matrices and structurally similar impurities.
For low-abundance impurities that challenge conventional UV workflows, our LC-MS testing capabilities enable sensitive and selective quantification of structurally specific impurities, transformation products, and difficult-to-resolve trace contaminants.
We quantify degradation-related impurities generated during thermal, oxidative, photolytic, hydrolytic, and processing stress, linking impurity growth to molecular instability and formulation vulnerability.
When impurity behavior is too complex for a single platform, we combine complementary tools such as HPLC testing, ion-based separations, spectroscopy, and targeted isolation workflows to improve confidence in both identity and level assignment.
BOC Sciences helps drug developers quantify critical impurities with analytical precision, practical workflow design, and molecule-specific problem solving.
We apply fit-for-purpose analytical technologies to quantify structurally diverse impurities, helping clients select appropriate testing workflows for trace contaminants, degradation products, elemental residues, moisture, and other critical quality-related components.
| Impurity Category | Typical Test Items | Common Analytical Methods |
|---|---|---|
| Genotoxic / Trace Impurities | Nitrosamines, sulfonate esters, and other trace reactive impurities | LC-MS/MS, GC-MS/MS |
| Volatile / Semi-Volatile Impurities | Residual solvents such as methanol, acetone, and related volatile components | Headspace Gas Chromatography (HS-GC) |
| Non-Volatile Organic Impurities | Process intermediates, by-products, and degradation products | HPLC |
| Elemental Impurities | Lead, cadmium, mercury, arsenic, palladium, and other elemental residues | ICP-MS, ICP-OES |
| Water Content | Crystal water or adsorbed moisture | Karl Fischer Titration |
| Biologics-Specific Impurities | Host cell proteins (HCP) and residual DNA | ELISA, qPCR |
| Routine General Tests | Sulfated ash, chlorides, sulfates, and related general quality indicators | Gravimetric Analysis, Titration, Ion Chromatography (IC) |
BOC Sciences supports impurity quantification across a broad range of pharmaceutical materials and development stages. From early route evaluation to mature analytical support, we tailor separation, detection, and sample preparation strategies to the chemical behavior of each project.
Share your molecule, impurity concerns, chromatograms, or current analytical challenges. Our team will design a practical quantification workflow matched to your sample type, impurity class, and development objective.
We review your molecule class, synthetic route, prior analytical data, suspected impurity sources, matrix complexity, and intended decision point to define the most suitable quantification strategy from the start.
Our scientists optimize sample preparation, chromatographic separation, detector settings, and integration logic to improve peak discrimination, response consistency, and low-level impurity visibility.
We verify impurity assignments through replicate analysis, orthogonal confirmation where needed, and standard- or response-based calculations to ensure the reported values are analytically defensible and decision-ready.
Clients receive structured quantitative results, impurity trend interpretation, and practical recommendations for follow-up work such as route refinement, targeted isolation, degradation study expansion, or analytical transfer.
Quantification becomes unreliable when structurally related impurities overlap with the main peak or with one another. BOC Sciences addresses this challenge through column screening, mobile phase optimization, selective detection, and alternative separation modes that improve peak purity assessment and reduce integration bias in crowded chromatograms.
Some impurities require far more than routine UV detection. We develop sensitive workflows for chemically reactive or very low-abundance species, using targeted mass spectrometric detection, fit-for-purpose sample preparation, and impurity-focused calibration strategies to improve selectivity and trace-level confidence.
Instability can create moving impurity targets over time and under stress. Our team maps degradation behavior, quantifies emerging species, and distinguishes meaningful chemical change from analytical artifact, helping clients identify the most relevant impurity markers for process and formulation decisions.
Early impurity methods often fail as projects mature and sample matrices become more complex. We help translate exploratory methods into more robust quantitative workflows by improving reproducibility, reducing matrix interference, and aligning the method with the practical needs of scale-up, stability work, and routine analytical support.
Partner with BOC Sciences for impurity quantification workflows that are scientifically rigorous, operationally practical, and tailored to the behavior of your molecule and sample matrix.
We tailor each workflow to the chemistry, polarity, stability, and likely impurity mechanisms of your target, rather than forcing every project through a generic platform method.
When a single technique is insufficient, we integrate complementary tools to improve impurity assignment confidence and strengthen quantitative interpretation for complex or low-level species.
Our results are presented in a way that helps scientific and project teams act—whether the next step is route optimization, impurity synthesis, stress testing, or additional analytical refinement.
BOC Sciences supports quantification of process impurities, degradation products, residual contaminants, elemental residues, and structurally complex low-level species across diverse pharmaceutical sample types.
Client Needs: A development team working on a heteroaryl small-molecule API observed a late-eluting impurity that increased after accelerated stress and interfered with routine area normalization.
Challenges: The impurity partially co-eluted with a noncritical matrix component under the client's existing reversed-phase method, making both trend analysis and peak integration inconsistent across batches.
Solution: BOC Sciences redesigned the gradient profile, screened alternative stationary phases, and introduced selective LC-MS confirmation to distinguish the degradant from the matrix peak. We then established a dedicated quantification workflow supported by focused stress samples and comparative detector-response review. For follow-up structure work, the project was aligned with our impurity isolation and identification capability.
Outcome: The revised method delivered stable peak assignment and reproducible quantification, enabling the client to track degradant growth confidently during formulation and storage studies.
Client Needs: A pharmaceutical partner needed targeted quantification of a potential reactive impurity present at very low abundance in a nitrogen-rich API process stream.
Challenges: Conventional UV detection lacked the selectivity required, and sample preparation conditions risked suppressing signal for the impurity of interest while amplifying background noise from related process components.
Solution: We developed a selective LC-MS workflow with optimized extraction conditions, impurity-focused calibration design, and targeted ion monitoring. Orthogonal review of precursor and product ion behavior improved assignment confidence, while careful carryover control reduced false positives in sequential injections.
Outcome: The client obtained a practical method for low-level impurity tracking across process lots, supporting better understanding of impurity origin and improved evaluation of process adjustments.
Client Needs: A biotech group developing a modified oligonucleotide required quantitative tracking of shortmer, deletion, and deprotected impurity species during process refinement.
Challenges: Multiple impurity classes displayed closely related retention behavior, broad peak shapes, and different response characteristics, limiting the usefulness of a single UV-only approach.
Solution: BOC Sciences implemented a fit-for-purpose impurity panel using ion-pair chromatography coupled with mass-selective confirmation, supplemented by method refinement support consistent with our method development, validation and transfer services. The workflow enabled category-specific tracking of key impurity families while improving cross-batch comparability.
Outcome: The client gained clearer visibility into impurity distribution and process sensitivity, allowing more efficient optimization of purification and deprotection steps.
Method selection should depend on impurity properties, expected levels, and sample matrix rather than on a single fixed platform. In general, related organic impurities and degradation products are often quantified by HPLC or UPLC, while trace-level or structurally complex targets may require LC-MS. Volatile or semi-volatile impurities are more suitable for GC-based methods, and elemental impurities often require ICP-MS-based analysis. At BOC Sciences, we first evaluate impurity class, co-elution risk, and sensitivity requirements, then build a practical analytical workflow so clients avoid spending time on methods that later need to be redeveloped.
Impurity quantification is not just about confirming whether impurities are present. It helps drug development teams understand what risk signals may emerge during synthesis, purification, storage, and stress conditions. For pharmaceutical clients, accurate quantification directly supports process optimization, route selection, batch consistency evaluation, and analytical planning. BOC Sciences can develop project-specific impurity quantification strategies based on sample origin, molecular characteristics, and development goals, helping clients identify critical impurities early, determine likely sources, and reduce technical uncertainty during later scale-up stages.
The challenge in trace impurity quantification is not only instrument sensitivity, but also sample preparation, matrix interference control, chromatographic resolution, and signal stability. In many projects, the real problems come from peak tailing, co-elution, background noise, or analyte instability rather than from insufficient instrument performance alone. A reliable strategy therefore requires coordinated optimization of pretreatment, separation conditions, detection mode, and system suitability. BOC Sciences supports trace impurity projects with tailored sample handling and analytical workflows that improve low-level signal discrimination and enhance result reproducibility across complex matrices.
These two impurity categories originate differently and should be interpreted using different logic. Process impurities are generally associated with starting materials, reagents, intermediates, or side reactions, whereas degradation products are more often linked to heat, light, oxidation, moisture, or formulation-related instability. In real development work, both may appear in the same chromatographic profile, so retention time alone is rarely sufficient for identification. A more dependable approach combines stress studies, synthetic route information, impurity profile trends, and structural characterization where needed. BOC Sciences integrates process understanding with analytical data to help clients determine impurity origin more efficiently and define more targeted control strategies.
Valuable impurity quantification data should help answer practical development questions: which step introduces the problem, how the impurity changes over time, and what process adjustment may reduce the risk. For example, an impurity that rises after a certain reaction endpoint may indicate overreaction, while a degradation peak that increases after concentration or storage may suggest thermal or solvent-related instability. Variability in residual or elemental signals may also reflect raw material differences, equipment contact, or purification inefficiency. By linking impurity levels with process parameters, development teams can improve synthetic routes, purification schemes, and scale-up strategies more effectively rather than treating impurity testing as an isolated analytical task.
We came in with a difficult impurity profile and several unresolved low-level peaks. BOC Sciences quickly identified where our method was failing and rebuilt the separation into something we could actually use for development decisions.
— Dr. Martin H., Senior Analytical Scientist
Their team handled a challenging trace impurity program with impressive technical discipline. The combination of mass-selective quantitation and practical interpretation helped us understand our process much faster.
— Elena R., CMC Project Manager
Quantifying oligonucleotide impurities had been a recurring bottleneck for us. BOC Sciences provided a much clearer impurity map and helped us separate true chemistry issues from method-related artifacts.
— Dr. Chen, Head of Process Development
What stood out was not only the analytical quality, but the way the results were translated into next steps. Their impurity quantification report directly informed our route optimization and follow-up isolation plan.
— James P., Director of Pharmaceutical Development
